Travere Therapeutics, Inc. (TVTX)
Market Cap | 586.89M |
Revenue (ttm) | 209.65M |
Net Income (ttm) | -87.05M |
Shares Out | 75.15M |
EPS (ttm) | -1.46 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 3,096,350 |
Open | 7.84 |
Previous Close | 7.81 |
Day's Range | 7.82 - 8.77 |
52-Week Range | 5.25 - 23.18 |
Beta | 0.53 |
Analysts | Buy |
Price Target | 20.57 (+137.8%) |
Earnings Date | Nov 7, 2023 |
About TVTX
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola a... [Read more]
Financial Performance
In 2022, TVTX's revenue was $212.02 million, a decrease of -6.80% compared to the previous year's $227.49 million. Losses were -$278.48 million, 54.6% more than in 2021.
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for TVTX stock is "Buy." The 12-month stock price forecast is $20.57, which is an increase of 137.80% from the latest price.
News

Travere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference
SAN DIEGO, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will present at the 6th Annual Evercore ISI HealthCONx Conference on Tues...

Travere Therapeutics Reports Third Quarter 2023 Financial Results
Received 430 new patient start forms for FILSPARI ® (sparsentan) in the third quarter of 2023; demand and payer coverage continued to grow

Travere Therapeutics Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM Respectively and Presented at the American Society of Nephrology (ASN) Kidney Week 2023
“The totality of data from the PROTECT study demonstrates FILSPARI is effective, safe and has an important place in the IgAN treatment landscape

Travere Therapeutics to Report Third Quarter 2023 Financial Results
SAN DIEGO, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2023 financial results on Tuesday, November 7, 2023, after the close...

Travere Therapeutics to Present Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023
Two late-breaking high-impact oral presentations of the Phase 3 PROTECT Study of FILSPARI ® (sparsentan) in IgAN and Phase 3 DUPLEX Study of sparsentan in FSGS

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on October 10, 2023, the Compensation Committee of its Board of Directors granted inducement...

Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA Nephropathy (IIGANN 2023)
SAN DIEGO, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present preliminary findings from the SPARTAN Study ...

Travere Therapeutics shares plunge as kidney-disease treatment has mixed results in trial
Travere Therapeutics Inc. shares TVTX dropped 37% premarket on Thursday after the company released data from a late-stage study of Filspari in IgA nephropathy, a rare kidney disease. In a head-to-head...

Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, Irbesartan
SAN DIEGO, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced topline two-year confirmatory secondary endpoint results from the Company's pivotal head-to-head...

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on September 10, 2023, the Compensation Committee of its Board of Directors granted inducem...

Travere Therapeutics Completes Sale of Bile Acid Product Portfolio to Mirum Pharmaceuticals
• Travere received $210 million at closing and is eligible for up to $235 million in potential sales-based milestone payments • Mirum has acquired Travere's rights and assets related to Cholbam ® and ...

Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics
FOSTER CITY, Calif. & SAN DIEGO--(BUSINESS WIRE)-- #alagillesyndrome--Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Thera...

Travere Therapeutics to Present at the 2023 Wells Fargo Healthcare Conference
SAN DIEGO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will present at the 2023 Wells Fargo Healthcare Conference on Thursday, S...

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Travere Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Travere Therape...

Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023
SAN DIEGO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company will present clinical data from the Phase 1/2 COMPOSE Study of pegtibatinase, a ...

Travere Therapeutics Reports Second Quarter 2023 Financial Results
• Received 417 new patient start forms for FILSPARI™(sparsentan) in the second quarter 2023, reflecting continued strong demand from nephrologists and patients with IgA nephropathy (IgAN)

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Travere Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 3, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Travere Therapeu...

Biotech stock Travere Therapeutics is trading at a deep discount: JPMorgan
Travere Therapeutics Inc (NASDAQ: TVTX) has been a disappointment for shareholders since early May but a JPMorgan analyst expects it to recover over the next 18 months. Travere Therapeutics shares hav...

Travere Therapeutics to Report Second Quarter 2023 Financial Results
SAN DIEGO, July 20, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report second quarter 2023 financial results on Thursday, August 3, 2023, after the close...

Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics
FOSTER CITY, Calif. & SAN DIEGO--(BUSINESS WIRE)-- #liverdisease--Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Th...

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Travere Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 7, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Travere Therapeuti...

INVESTIGATION ALERT: The Gross Law Firm Notifies Shareholders of Travere Therapeutics, Inc. of an Investigation and Potential Class Action Lawsuit - (NASDAQ: TVTX)
NEW YORK , July 6, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Travere Therapeutics, Inc.: The investigation focuses on whether Travere issued false and/or m...

INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Travere Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 4, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Travere Therapeuti...

TVTX ALERT: The Law Offices of Vincent Wong Investigate Travere Therapeutics, Inc. for Potential Violations of Securities Laws
NEW YORK , July 3, 2023 /PRNewswire/ -- Attention Travere Therapeutics, Inc. ("Travere") (NASDAQ: TVTX) shareholders: The Law Offices of Vincent Wong announce that an investigation has commenced into ...

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Travere Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 3, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Travere Therapeuti...